Literature DB >> 1739630

Prognostic impact of chromosome aberrations in ovarian cancer.

T Pejovic1, A Himmelmann, S Heim, N Mandahl, U M Flodérus, S Furgyik, B Elmfors, G Helm, H Willén, F Mitelman.   

Abstract

Clinico-cytogenetic correlations were assessed in 88 patients with malignant ovarian tumours. Cytogenetic analysis of the primary tumours yielded normal karyotype (N) in 33 patients and abnormal karyotypes (A) in 55 patients. Within the A group, seven tumours had simple abnormalities (AS), i.e., numerical changes only or a single structural aberration, and 48 had karyotypes with complex aberrations (AC). A correlation analysis between groups N and A revealed that cytogenetic abnormalities were more often found among seropapillary tumours, and that cases with abnormal karyotypes on average were of higher stage and more often had residual tumour mass after initial surgery (P less than 0.05 for all variables). When the three groups N, AS, and AC were compared, they were found to be significantly different with regard not only to the three parameters mentioned above, but now tumour grade also appeared to correlate with karyotypic pattern (P = 0.001), with poorly differentiated tumours having the most complex karyotypes. In a correlation analysis between karyotypic pattern and survival, group A patients had shorter survival than group N (P = 0.049). In the corresponding analysis between groups N, AS, and AC, the differences were also significant (P = 0.039), with shorter survival in group AC than in groups N and AS. Stage, grade, residual tumour after primary surgery, and performance status also correlated with survival time. A multivariate analysis identified abnormal karyotype as being independently associated with short survival in advanced clinical stages (P = 0.030) of ovarian carcinoma. We conclude that cytogenetic analysis of tumour cells may be of clinical value in the assessment of prognosis in patients with malignant ovarian tumours.

Entities:  

Mesh:

Year:  1992        PMID: 1739630      PMCID: PMC1977727          DOI: 10.1038/bjc.1992.56

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Malignant fibrous histiocytomas with a 19p+ marker chromosome have increased relapse rate.

Authors:  A Rydholm; N Mandahl; S Heim; A Kreicbergs; H Willén; F Mitelman
Journal:  Genes Chromosomes Cancer       Date:  1990-11       Impact factor: 5.006

2.  Consistent occurrence of a 19p+ marker chromosome and loss of 11p material in ovarian seropapillary cystadenocarcinomas.

Authors:  T Pejovic; S Heim; N Mandahl; B Elmfors; U M Flodérus; S Furgyik; G Helm; H Willén; F Mitelman
Journal:  Genes Chromosomes Cancer       Date:  1989-11       Impact factor: 5.006

3.  Human ovarian carcinomas: correlation of malignancy and survival with the expression of epidermal growth factor receptors (EGF-R) and EGF-like factors (EGF-F).

Authors:  T Bauknecht; I Janz; M Kohler; A Pfleiderer
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

4.  Modal DNA value and chromosome number in ovarian neoplasia. A clinical and histopathologic assessment.

Authors:  N B Atkin
Journal:  Cancer       Date:  1971-05       Impact factor: 6.860

5.  Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary.

Authors:  G D Malkasian; L J Melton; P C O'Brien; M H Greene
Journal:  Am J Obstet Gynecol       Date:  1984-06-01       Impact factor: 8.661

6.  Clinical significance of abnormal nuclear DNA content in serous ovarian tumors.

Authors:  P J Klemi; H Joensuu; P Kiilholma; J Mäenpää
Journal:  Cancer       Date:  1988-11-01       Impact factor: 6.860

7.  Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.

Authors:  A Berchuck; G C Rodriguez; A Kamel; R K Dodge; J T Soper; D L Clarke-Pearson; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1991-02       Impact factor: 8.661

8.  Clonogenic growth in vitro: an independent biologic prognostic factor in ovarian carcinoma.

Authors:  C Dittrich; E Dittrich; P Sevelda; M Hudec; H Salzer; T Grunt; J Eliason
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

9.  Bilateral ovarian carcinoma: cytogenetic evidence of unicentric origin.

Authors:  T Pejovic; S Heim; N Mandahl; B Elmfors; S Furgyik; U M Flodérus; G Helm; H Willén; F Mitelman
Journal:  Int J Cancer       Date:  1991-02-01       Impact factor: 7.396

10.  Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).

Authors:  S Marsoni; V Torri; M G Valsecchi; C Belloni; U Bianchi; G Bolis; C Bonazzi; N Colombo; A Epis; G Favalli
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

View more
  3 in total

1.  VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.

Authors:  Karen Gambaro; Michael C J Quinn; Paulina M Wojnarowicz; Suzanna L Arcand; Manon de Ladurantaye; Véronique Barrès; Jean-Sébastien Ripeau; Ann M Killary; Elaine C Davis; Josée Lavoie; Diane M Provencher; Anne-Marie Mes-Masson; Mario Chevrette; Patricia N Tonin
Journal:  Mol Oncol       Date:  2013-01-16       Impact factor: 6.603

Review 2.  Comparative oncology: what dogs and other species can teach us about humans with cancer.

Authors:  Joshua D Schiffman; Matthew Breen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-19       Impact factor: 6.237

3.  Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.

Authors:  Jane Bayani; Paula Marrano; Cassandra Graham; Yingye Zheng; Lin Li; Dionyssios Katsaros; Heini Lassus; Ralf Butzow; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2010-08-11       Impact factor: 6.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.